

# Alkyl Amines Chemicals Limited



Reg. Office: 401-407, Nirman Vyapar Kendra, Plot No. 10, Sector 17, Vashi, Navi Mumbai - 400 703. INDIA Tel.: 022-6794 6600 • Fax: 022-6794 6666 • E-mail : alkyl@alkylamines.com • Web: www.alkylamines.com

February 2, 2021

To,

BSE Ltd.

P. J. Towers, Dalal Street,

Mumbai - 400 001.

**SCRIPCODE:** 506767

The National Stock Exchange of India Ltd.

Exchange Plaza, Bandra Kurla Complex,

Bandra (E),

Mumbai - 400 051.

**SYMBOL: ALKYLAMINE** 

Sub: Outcome of Board Meeting held on February 2, 2021 and Disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs;

The Board of Directors of the Company at its meeting held on February 2, 2021, has considered and approved inter-alia the following:

#### 1. Unaudited Financial Results:

The Board of Directors has approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2020. We enclose herewith the Unaudited Financial Results of the Company, along with the Auditors' Limited Review Report thereupon.

#### 2. Interim Dividend for the FY 2020-21 and fixing of Record Date:

The Board of Directors has declared an interim dividend of Rs. 10/- per Equity Share of Rs. 5/- each (i.e. 200%) for the financial year 2020-21.

Further, in terms of Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Record Date for the interim dividend is fixed at February 15, 2021. The dividend will be paid on March 1, 2021.

#### 3. Sub-division of Equity Shares:

The Board of Directors has considered and approved the following business matters subject to the approval of shareholders through postal ballot:

- a) Sub-division of Equity Share of face value of Rs.5/- each fully paid up to Equity Shares of face value of Rs. 2/- each fully paid up at the Record date to be determined as authorized by the Board of Directors, subsequent to the approval of the shareholders through Postal Ballot.
- b) The alteration of "Capital Clause Clause V" of the Memorandum of Association of the Company.

MUMBA



The detailed disclosures as regards the sub-division pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the relevant SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015, is enclosed herewith as Annexure — A to this intimation.

The Board of Directors has also approved the Notice of Postal Ballot to be sent to the members for their approvals to be sought for the aforesaid business matters.

#### 4. Enhancement of capacity for Aliphatic Amines:

The Company has established a leading position in domestic market and a presence in international market with a reputation for reliable service and quality products. With the growing demand for Company's products, the Board of Directors has approved the investments for enhancement of capacity for Aliphatic Amines at Kurkumbh and Patalganga sites in Maharashtra.

The details required pursuant to the requirements of the SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015, are enclosed herewith as Annexure – B.

#### 5.Appointment of Chief Financial Officer:

The Board of Directors has approved appointment of Mr. Kirat Patel, Executive Director as Chief Financial Officer of the Company with immediate effect. The details required pursuant to the requirements of the SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015, are enclosed herewith as Annexure — C.

The Board Meeting commenced at 11:30 A.M. and concluded at 13:45 P.M. Kindly take the above information on your records.

MUMBAI

Thanking you,

Yours faithfully,

For ALKYL AMINES CHEMICALS LTD.

Chintamani D. Thatte

General Manager (Legal) & Company Secretary

& Compliance Officer

Encl.: As above.

N. M. RAIJI & CO.

Chartered Accountants Universal Insurance Building, Pherozeshah Mehta Road, Mumbai-400 001. INDIA

Telephone:

2287 0068 2287 3463

Telefax : 91 (22) 2282 8646

E-mail: nmr.ho@nmraiji.com

## INDEPENDENT AUDITOR'S REVIEW REPORT ON **REVIEW OF INTERIM FINANCIAL RESULTS**

The Board of Directors Alkyl Amines Chemicals Limited 401-407, Nirman Vyapar Kendra Plot No.10, Sector 17, DBC, Vashi Navi Mumbai - 400703

- We have reviewed the accompanying statement of unaudited financial results of Alkyl 1. Amines Chemicals Limited ("the Company"), for the quarter and nine months ended December 31, 2020 ("the Statement"), together with the relevant notes thereon (the "Statement"). This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") as amended, which has been initialled by us for identification purposes. The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015, and relevant amendment rules thereafter, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.



- 3. A review of interim financials is limited primarily to inquiries of company personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. M. Raiji & Co. Chartered Accountants Firm Registration No.108296W



Vinay Dattatray Balse Digitally signed by Vinay Dattatray Balse Date: 2021.02.02 13:46:26 +05'30'

Vinay D. Balse Partner

Membership. No.: 039434

UDIN No. 21039434AAAAAQ4817

Place: Mumbai

Date: February 2, 2021



# Alkyl Amines Chemicals Limited



Reg. Office: 401-407, Ninnan Vyapar Kendra, Plot No. 10, Sector 17, Vashi, Navi Mumbai - 400 703. INDIA Tel.: 022-6794 6600 • Fax: 022-6794 6666 • E-mail: alkyl@alkylamines.com • Web: www.alkylamines.com

#### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31,2020

Rs.in Lakhs (Except per share data)

_		(Except per share data					
Sr.		Quarter ended			Nine Months ended Year ende		
Nσ.	Particulars	Dec 31, 2020	Sep 30, 2020	Dec 31, 2019	Dec 31, 2020	Dec 31, 2019	Mar 31, 2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
١.	Revenue from Operations	32,388.57	29,126.83	25,691.11	86,030.62	75,811.24	99,287.76
li.	Other Income	165.98	270.58	216.72	554.62	439.22	701.16
	Total Revenue (I+II)	32,554.55	29,397.41	25,907.83	86,585.24	76,250.46	99,938.92
11/	Expenses						
-0.0000	Cost of Materials Consumed	12,771.33	12,035.98	11,445,87	35,600.75	36,567.32	47,621.68
	Changes in Inventories of Finished Goods	12,171.00	12,000.00	11,440.01	30,000.74	00,007.02	47,021.00
	and Work-in-Progress	(102.10)	356.00	16.02	273.71	1,091.94	827.78
	Employee benefit costs	2,398.28	2,130.24	1,903,79	6,520,20	5,268,41	6,964,15
	Finance Costs	137.06	161.85	213,45	491.27	836,07	1,025.39
	Depreciation and Amortisation Expense	756.54	721.29	680,26	2,179.79	1,970.74	2,690.98
	Other Expenses	5,012.05	5,078.42	5,067.97	14,062.61	13,939.84	18,172,17
	Total Expenses (IV)	20,973.16	20,483.78	19,327,36	59,128.33	59,674.32	77,302.15
-	A CONTRACTOR OF THE PROPERTY O						T. 100
120000	Profit before Exceptional Items and Tax (III-IV)	11,581.39	8,913.63	6,580.47	27,456.91	16,576.14	22,686.77
	Exceptional Items	-	-	3,284.16		3,284.16	3,284.16
VIL.	Profit before tax (V+VI)	11,581.39	8,913.63	9,864.63	27,456.91	19,860.30	25,970.93
	Tax Expense :						
	Current Tax	3,133.12	2,182.39	1,694.50	6,861.47	3,950.42	5,403.55
	Deferred Tax	(340.77)	184.04	491.88	(11,40)	(763.30)	(1,030.04
	Tax adjustments of earlier years	340.13	-	(30.40)	332,60	65.87	69.30
	Total Tax Expenses	3.132.48	2,366.43	2,155.98	7,182,67	3,252,99	4,442.81
IX.	Net Profit for the period/year (VII-VIII)	8,448.91	6,547.20	7,708.65	20,274.24	16,607.31	21,528.12
	Other Comprehensive Income/ (Expense)						
	a) Items that will not be reclassified to profit or loss				6		
1	- Remeasurement gain/(losses) on defined benefit plans						
1	Language (section)	(136,33)	(22.02)	(49.65)	(237.84)	(158.04)	(171.17
	<ul> <li>b) Income tax relating to items that will not be reclassified</li> </ul>						
	to profit or loss	35.22	6.10	11.45	58.91	38.55	40.38
	c) Items that may be reclassified to profit or loss						
	- Deferred gains/(losses) on cash flow hedges reserves	(5.73)	(154.66)	(64.69)	(106.86)	(0.06)	0.80
	d) Income tax relating to items that may be reclassified to		· · · · · · · · · · · · · · · · · · ·			Ç.,,	
	profit or loss	1.02	37.29	14.50	26.48	0.01	70.10
	Other Comprehensive Income / (Expense) for the	1.02	37.23	14,50	20.40	0.01	(0.18)
Ì	period/year (Net of Tax)	(105.82)	(133,29)	(88.29)	(050.24)	(440 CA)	/400 471
YI.	Total Comprehensive Income for the period/year (IX+X)	(103.02)	(133.23)	(00.58)	(259.31)	(119.54)	(130.17)
Δ1,	Total Comprehensive micome for the period/year (IX4X)	8,343.09	6,413.91	7,620.36	20,014.93	16,487,77	21,397.95
		194				Pro 1 1000 100 100 100 100 100 100 100 100	
XII.	Paid up Share Capital	1,020.64	1,020.50	1,019.82	1,020.64	1,019.82	1,019.82
XIII.	Face Value of Share (Rs)	5.00	5.00	5.00	5.00	5.00	5.00
XIV.	Earnings Per Equity Share	, mark 400				5.00	5.00
	Basic (Rs)	41.39	32.08	37.79	99.32	81.42	105.55
	Diluted (Rs)	41,29	32.00	37.69	99.07	81.21	









#### Notes:

- The above unaudited financial results have been reviewed and recommended by the Audit Committee at their meeting held on February 2, 2021, and approved by the Board of Directors at their meeting on the same date. The Limited Review, as required under the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended December 31, 2020 and they have expressed an unmodified opinion on the same.
- 2 The Company is primarily engaged in the business of "Specialty Chemicals". Accordingly, there are no reportable Segments.
- There has not been any adverse impact of COVID-19 on the Company's business operations so far. The Company expects that the demand for its products from the pharmaceutical sector will continue. However, the Company will continue to evaluate the pandemic related uncertainty with respect to its business and economic conditions and update its assessment.
- The Board of Directors have declared an interim dividend at the rate of 200% (i.e. Rs 10/- per share) on 2,04,12,711 Equity Shares of Rs 5/- each fully paid up.
- 5 The Board of Directors have approved, subject to approval of shareholders through postal ballot, the sub-division of Equity Share of face value of Rs 5/e each to Equity Shares of face value of Rs.2/e each.
- 6 The Board of Directors have approved the investments for the enhancement of capacity for Aliphatic Amines at Kurkumbh & Patalganga sites in Maharashtra.

7 Figures for the previous periods have been regrouped and reclassified, wherever necessary.

FOR ALKYL AMINES CHEMICALS LTD.

Olgitally signed by YOGESH M YOGESH M YOGESH M YOGESH M YOGESH M YOTHARI KWYOTHARI CHAIRMAN & MANAGING DIRECTOR



Place : Mumbai Date : February 02,2021





#### ANNEXURE - A

## Sub-division of shares of the Company:

Sr. No	Particulars	Details			
1.	Split Ratio	Equity Share of face value of Rs.5 each fully paid up will be sub divided into Equity Shares of face value of Rs.2/- each fully paid up.			
2.	Rationale behind the split	Note Upon sub-division of face of value of each share from Rs 5/to Rs 2/-, all fractions resulting from the sub-division of shares shall be consolidated into whole Equity shares and the same will be disposed-off at the market price and the net proceeds (less expenses, if any) will be distributed proportionately, as far as practicable, to the members concerned.  To facilitate more liquidity of the Company's			
۷.		equity shares in the stock market.			
3.	Pre and post share capital  – authorized, paid-up and subscribed	Based on the ratio of split of shares, the share capital of the company pre and post will be as follows:  Authorised Share Capital			
		Pre sub-division  Rs. 30,00,00,000/- divided into 3,00,00,000 Equity shares of Rs.5 each and 15,00,000 Cumulative Redeemable Preference Shares of Rs. 100/- each			
		Paid-up and Subscribed Share Capital:  The Pre Sub-division and Post Sub-Division Share Capital will be disclosed by the Company as on the Record Date to be decided for the sub-division.  As authorized by the Board, the Chairman and Managing Director and/or Executive Directors and/or Company Secretary of the Company shall decide the Record Date subsequent to the approval of the shareholders of the Company through Postal Ballot			
4.	Expected time of completion	Approximately within 3 months from the approval of the shareholders of the Company through the			





	530 1800	200		
LI A		1	74	
- Α\		K	V I	
174	زم پ	1.4		
1	Street, or other Designation of the last o			

		Postal Ballot.
5.	Class of shares which are sub-divided	Existing Equity Shares of the face value of Rs. 5/-each.
6.	Number of equity shares of each class pre and post- split	Refer serial no.3 above
7.	Number of shareholders who did not get any shares in consolidation and their pre-consolidation shareholding	Not Applicable.





#### ANNEXURE - B

### **Enhancement of capacity for Aliphatic Amines:**

Sr. No.	Details of the event	Information of such event(s)		
1	Existing Capacity	80,000-90,000 MTs per annumof various Aliphatic Amines		
2	Existing Capacity utilization	Between 80% to 90%currently		
3	Proposed Capacity addition	Approx. 30-40% additional capacities in Aliphatic Amines depending on mix.		
4	Period within which the Between 15 months to 20 months proposed capacity is to be added			
5	Investment required	Between Rs. 300 - Rs. 350 crores approximately		
6	Mode of financing	Internal accruals		
7	Rationale	In anticipation of increasing demand in the domestic and exports market for various Amines, the Company feels it is prudent to expand its capacities to fulfill the demand		







# ANNEXURE - C Appointment of Mr. Kirat Patel as Chief Financial Officer (CFO) of the Company

Sr. No.	Details of the event	Information of such event(s)		
1	Reason of Change viz. Appointment, Resignation, Removal, death or otherwise	Section Control Control Control of Control of Control Control of Control Control of Cont		
2	Date of appointment/ cessation (as applicable) Term of appointment	Appointment with immediate effect  No change in present terms of appointment		
3	Brief Profile (in case of appointment)	Mr. Kirat Patel, aged 68, is B. Tech., Mechanical Engineering from Indian Institute of Technology, Bombay, and MMS (Finance) from Jamnalal Bajaj Institute of Management, Mumbai, and has been working with the Company since its inception. He has been Executive Director of the Company since 1996 and has vast, varied and unique experience of more than 40 years in Operations, Commercial as well as Finance and Accounts.		
4	Disclosure of Relationship between Directors (in case of appointment of a Director)	Not applicable		



